REUTERS: Pfizer Inc on Monday reported a 30per cent rise in quarterly profit, helped by demand for its branded treatments such as Ibrance, Eliquis and Xeljanz. Pfizer, which was scheduled to report its second-quarter earnings on Tuesday, also said it would combine Upjohn, its off-patent drugs …
